Pharmaceutical Technology Europe- February 2022

Pharmaceutical Technology Europe February 2022

Issue link: https://www.e-digitaleditions.com/i/1450659

Contents of this Issue

Navigation

Page 17 of 36

18 Pharmaceutical Technology Europe BIO/PHARMA OUTSOURCING INNOVATION eBOOK 2022 P h a r mTe c h . c o m Development A ccording to market research, the size of the outsourcing sector serving the pharmaceutical and biotechnology industries is expected to ex- pand, reaching $99.4 billion by 2028 (1). Demand for outsourced services is being driven by several factors, such as high demand for biologics and small molecules, a lack of in-house expertise, and rising costs associated with in-house development capabilities. To find out more about how demands have changed for outsourcing partners providing method development ser- vices and the trends affecting this sector, Pharmaceutical Technology Europe spoke with Jerry "Jr." Mizell, senior di- rector, Analytical Services, Metrics Contract Services. Changing demands PTE: Could you provide a brief overview of how the demands have changed over the years for outsourcing partners in terms of method development services? Mizell (Metric s Contrac t Ser vices): Nowadays, there is an increased demand for sound methods to be developed early in t he product life c ycle. More customers wa nt rugged and robust methods in place as early in the devel- opment process as possible, and they want methods that require minimal changes as their programmes advance to commercial phases. Based on the experience of Metrics Contract Services, customers a lso want to develop qua lit y control (QC)- friendly methods that help maximize laboratory efficiency in the commercial phase. Across various methods developed in recent years, dissolution, in particular, has been in the spotlight. A comprehensive approach to dissolution should produce a discriminating method that can demonstrate that an adequate drug product has been manufactured. Current customer expectations also demand a detailed dissolution method development report describing how the dissolution procedure was derived. This is especially important for new drug applications (NDAs). ANDRII YAL ANSKYI - STOCK.ADOBE.COM Method Development in Demand Felicity Thomas Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology Europe- February 2022 - Pharmaceutical Technology Europe February 2022